According to new research, quality has overtaken cost as a priority in plans for automating adverse event reporting. John Price reveals the drivers and barriers to change.
In safety & pharmacovigilance, the requirement to capture, sift and process real-world adverse event data is vast and growing all the time. Why then, writes John Price, is the discipline lagging in its application of smart technology?